SCHEMBL3660951

SCHEMBL3660951

FC(F)(F)c1cccc(N(c2ccccc2)C2CCNCC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.56
SLC6A2 P23975 5/20 0.56
HTR2C P28335 5/20 0.55
DCUN1D1 Q96GG9 1/20 0.48
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
CYP2D6 P10635 1/20 0.45
HRH1 P35367 1/20 0.45
SCN1A P35498 1/20 0.45
SCN2A Q99250 1/20 0.45
SCN3A Q9NY46 1/20 0.45
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTR1D P28221 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18271346 0.86 SLC6A2 (0.56) SLC6A4SLC6A2HTR2CMEN1KMT2A
Hydrochloric Acid SCHEMBL18263754 0.84 SLC6A2 (0.55) SLC6A4SLC6A2HTR2CMEN1KMT2A
SCHEMBL3837450 0.83 SLC6A2 (0.62) SLC6A4SLC6A2HTR2CMEN1KMT2A
SCHEMBL18270998 0.83 SLC6A2 (0.57) SLC6A4SLC6A2HTR2CSIGMAR1TACR1
Hydrochloric Acid SCHEMBL18263755 0.82 SLC6A2 (0.56) SLC6A4SLC6A2HTR2CMEN1KMT2A
Hydrochloric Acid SCHEMBL18263847 0.82 SLC6A2 (0.60) SLC6A4SLC6A2HTR2CMEN1KMT2A
Trifluoroacetic Acid SCHEMBL31055380 0.80 SLC6A2 (0.50) SLC6A4SLC6A2HTR2CDCUN1D1MEN1
SCHEMBL4315201 0.79 SLC6A4 (0.61) SLC6A4SLC6A2HTR2CDCUN1D1MEN1
SCHEMBL18270999 0.78 SLC6A4 (0.57) SLC6A4SLC6A2MEN1KMT2ALMNA
SCHEMBL3640568 0.77 HTR2C (0.49) SLC6A4SLC6A2HTR2CMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231601-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-06-18 EP disclosed
US-8258306-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2012-09-04 US disclosed
US-20100298341-A1 Glycine Transporter-1 Inhibitors AMGEN INC. 2010-11-25 US disclosed
EP-2231601-A2 GLYCINE TRANSPORTER-1 INHIBITORS Amgen, Inc (US) 2010-09-29 EP disclosed
WO-2009075857-A2 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298341-A1 Glycine Transporter-1 Inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A4 16/4885SLC6A2 7/4885HTR2C 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.